Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "SPIRONOLACTONE TABLETS" OBTAINS APPROVAL FOR NEW INDICATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"SPIRONOLACTONE TABLETS" OBTAINS APPROVAL FOR NEW INDICATION

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company", together with its subsidiaries, the "Group") announces that "Spironolactone Tablets", a diuretic developed by the Group, has obtained the notice of approval of supplemental applications issued by the National Medical Products Administration of the People's Republic of China, approving the addition of specification of 100mg (the first domestic specification of its kind) and new indication, applicable to the treatment of heart failure, hypertension, edema related to liver cirrhosis and nephrotic syndrome, as well as primary aldosteronism.

Spironolactone is a competitive inhibitor of aldosterone, acting on distal convoluted tubules and collecting ducts of kidney, with a slow and long-lasting diuretic effect. It is unanimously recommended by many domestic guidelines on diagnosis and treatment, including the 2019 edition of "Guidelines on Primary Diagnosis and Treatment of Chronic Heart Failure", for the treatment of heart failure and hypertension. Its main applicable departments include cardiovascular department, hepatology department, nephrology department, endocrinology department, urology department, etc. Spironolactone Tablets have been included in the 2019 National Drugs Reimbursement Drug List (Class A) and the 2018 National Essential Drugs Catalogue.

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 15 September 2020

As at the date of this announcement, the Board comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan, Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.